Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT05039216
Recruiting Observational

Biobank for Inflammatory Chronic Diseases and Osteoporosis

NCT05039216 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Toulouse
Phase
Observational
Started
2021-09-13
Last updated
2026-03-19

Condition(s) studied

Rheumatoid ArthritisPsoriatic ArthritisSpondyloarthritisOsteoporosis

Investigational drug(s) / intervention(s)

Blood sampling →

Blood sampling: 4 tubes of 7 mL will be sampled

Study summary

The aim of this study is to constitute a biobank for patients followed in the Rheumatology center of Toulouse University Hospital for a chronic inflammatory rheumatism including rheumatoid arthritis (RA), spondyloarthritis(SpA), and psoriatic arthritis (PsA) or a chronic bone disease including osteoporosis in order to identify biomarkers associated with therapeutic response.

Eligibility

Sex
ALL
Min age
18 Years
Max age
99 Years
Healthy volunteers
No
Inclusion Criteria: * Chronic inflammatory rheumatism including RA, SpA or PsA or patients with primary or secondary osteoporosis * With National Health Assurance * Able to consent to the study Exclusion Criteria: * Pregnancy or breastfeeding * Not able to give a consent * Severe anemia (Hb\<10g/L)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Purpan University Hospital Toulouse France Recruiting

More University Hospital, Toulouse trials in France

Adapted Physical Activity for Children Treated With Cancer and Insulin Sensitivity Recruiting
Neurofeedback-EEG Rehabilitation Protocol on Motor Recovery in the Subacute Phase Post-stroke (CUSTOM-NF-STROKE) Recruiting
Molecular Analysis of Endoscopic Cytology Samples Supernatant in Pulmonary Nodules Recruiting
Periodontal Microbiota of Patients Candidates for Bariatric Surgery With Body Mass Index Greater Than 30 Recruiting
Effects of an Intensive Rhythmic Dance Program on Learning Skills in Children With Cerebral Palsy Recruiting

Other trials for the same condition

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs Active, not recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis. Recruiting
Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis Recruiting
A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and Ps Active, not recruiting
HLA B Leader in Patients With Psoriatic Arthritis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05039216 on ClinicalTrials.gov ↗ ← All trials in France